Articles by Ian Sanne

Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care

Stevens, Wendy S.; Gous, Natasha M.; MacLeod, William B.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 76(1):65-73, September 1, 2017.

Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa

Gous, Natasha M.; Scott, Lesley E.; Potgieter, Johan; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 71(2):e34-e43, February 1, 2016.

Patient Retention From HIV Diagnosis Through One Year on Antiretroviral Therapy at a Primary Health Care Clinic in Johannesburg, South Africa

Clouse, Kate; Pettifor, Audrey E.; Maskew, Mhairi; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(2):e39-e46, February 1, 2013.

Associations Between HLA-DRB1*0102, HLA-B*5801, and Hepatotoxicity During Initiation of Nevirapine-Containing Regimens in South Africa

Phillips, Elizabeth; Bartlett, John A.; Sanne, Ian; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(2):e55-e57, February 1, 2013.

Scale-up of HIV Treatment Through PEPFAR: A Historic Public Health Achievement

El-Sadr, Wafaa M.; Holmes, Charles B.; Mugyenyi, Peter; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 60:S96-S104, August 15, 2012.

Natural Killer Cell Activation Distinguishes Mycobacterium tuberculosis–Mediated Immune Reconstitution Syndrome From Chronic HIV and HIV/MTB Coinfection

Conradie, Francesca; Foulkes, Andrea S.; Ive, Prudence; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 58(3):309-318, November 1, 2011.

Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and ...

Sanne, Ian; Piliero, Peter; Squires, Kathleen; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 32(1):18-29, January 1, 2003.

Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and ...

Sanne, Ian; Piliero, Peter; Squires, Kathleen; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 32(1):18-29, January 2003.